Biosimilar User Fee Revenue Missed Estimates Again In FY 2019, Spending Reduced
Executive Summary
US FDA said that total BsUFA obligations also decreased compared to estimates, but maintains optimism about future revenue increases.
You may also be interested in...
FDA Rebates Biosimilar Fees And Limits Generic Fee Hike
The generic drug user fee could have jumped substantially to ensure operating reserves were sufficient, but the FDA decided against it, and biosimilar program reserves were too high, so the agency reduced the amount it will need.
US FDA Rebates Biosimilar Fees, Limits Generic Fee Hike In FY 2022
The generic drug user fee could have jumped substantially to ensure operating reserves were sufficient, but the FDA decided against it, and biosimilar program reserves were too high, so the agency reduced the amount it will need.
BsUFA III Negotiations Nearly Done; Commitment Letter Being Written
Supplement approval timeline and regulatory science issues apparently have been resolved.